by Raynovich Rod | Sep 22, 2017 | 2023-24 Life Science Portfolios, Biopharmaceuticals
Biotech Bull Market: XBI is leader for 2017 and Over Five Years The FBT First Trust Arca Outperformed Up 157% Over Five Years In 2016 the Sector Underperformed After the 2015 Downdraft Here is our July 2013 review of several top Life Science Funds and ETFs . Over five...
by Raynovich Rod | Sep 14, 2017 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Markets Stable After Major FED Meeting: On Course for Gradual QT(Quantitative Tightening) FED to shrink assets by year end, 2 yr TSY up to 1.43% yield. Biotech stocks up slightly near September Top IBB $332.75, XBI $85.17. Large caps green: growth and value perceived:...
by Raynovich Rod | Sep 5, 2017 | 2024 Rayno Biopharmaceuticals Portfolio
Biotech Bull Market 2017 Performance as of 9/5/17 Rayno Biopharmaceutical Portfolio outperforms the market. XBI was the Best Play up 41.88% YTD. Biotech stocks broke through the July sector highs as tracked by major ETFs. However we are still about 25% off the July...
by Raynovich Rod | Aug 30, 2017 | Biopharmaceuticals
M&A Boosts Biotech Stocks For Third Day Gilead Sciences (GILD) and bluebird bio (BLUE) Both Soar Today Biotech Sector Back to 2017 Highs The prospect of more M&A boosts biotech stocks for a third day this week. The large cap based IBB was up 1.87% today and...
by Raynovich Rod | Aug 28, 2017 | Biopharmaceuticals
Update-11:30am Aug 28 Green Screen in Biotech Especially CAR-T Plays (BLUE,CLLS,JUNO) NASDAQ up a tad 0.21%, but broad market flattish. Biotech Deal Boosts ETFs: FBT up 2.71%, IBB up 1.53%, XBI up 2.53%. Bellwether Celgene (CELG) up 1.4%. AMGN up 1.24%, BIIB up 2.67%,...
by Raynovich Rod | Aug 1, 2017 | Biopharmaceuticals
Rayno Large Cap Biopharma Earnings Summary 8/1/17 Biotech Stocks Hit Highs in Mid-July up 18%, 30% on XBI (Click on “urls” below for Company Press Release) All the large cap biopharmaceutical earnings have come in except Regeneron (REGN) which will report...
by Raynovich Rod | Jul 25, 2017 | Biopharmaceuticals
Update-2 7/31 After Close: Biotechs Remain Weak But No Sell Signal As we track the XBI over the past 5 days we are about 3.2% off highs from $82 down to $78.17. Although the XBI has been our top ETF pick since January 2017 we recently put new buys on hold and...
by Raynovich Rod | Jul 13, 2017 | Biopharmaceuticals
Update after close 7/13: Health Care draft bill appears to have stabilized biotech despite opposition. ETFs end in green but XLV is flat. More analysis is coming tomorrow. ========= It’s Vacation Time We are out on vaca until Monday the 17th. Here are some...
by Raynovich Rod | Jul 1, 2017 | 2024 Rayno Biopharmaceuticals Portfolio
Big Biotech Gains for Stocks in First Half Rayno Life Science Picks Top Winners YTD: Foundation Medicine (FMI) up 124.6%, bluebird bio (BLUE) up 70.26%, XBI up 20.9%. Large cap winners since inception: Abbvie (ABBV) and Roche ADR (RHHBY). 6/27 Take some profits on XBI...
by Raynovich Rod | Jun 22, 2017 | Biopharmaceuticals
CAR-T Therapies on Solid Tumors Here is an excellent summary by BIOtechNow Editors on the application of CAR-T (Chimeric Antigen Receptor) T-Cell therapies on solid tumors. Up until now CAR-T shows great promise against blood cancers but challenges remain for solid...